THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTION

摘要: The emergence of percutaneous catheter procedures for the restoration blood flow in occluded atherosclerotic coronary arteries introduced acute and potentially severe local vascular injuries. These balloon-device–based generated locally injured surfaces that could be highly attractive to platelets carried risk rapid vessel closure. available antiplatelet agents, such as aspirin, were generally weak nonspecific inadequate fully protect against this new type provocation. An alternative pathway involving a platelet adhesion receptor, however, was identified promising target potent efficacy required these interventional procedures. an integral membrane receptor termed GPIIb/IIIa (in integrin nomenclature, Nb β 3 ). On activated platelets, binds natural ligand, fibrinogen, interconnect into thrombotic aggregates. search selective antagonists aggregation led development monoclonal antibody small-molecule competitive mimic ligand(s) receptor. This review will focus on abciximab. inhibition extensively studied vitro , well-established animal models thrombosis several large clinical trials. More than decade continued research has yielded further details structural complexity, conformational responsiveness signaling connections not envisioned during early drug development. Abciximab other continue provide insights contribute effort refine anti- therapy.